Epicutaneous sensitization with ovalbumin induction with tape stripping in mice is a useful model.



Atopic dermatitis (AD) is a common allergic inflammatory disease of the skin that is characterized by intense pruritus and chronic eczematous plaques and is often associated with a personal or family history of allergic disease. In addition, it is the most common chronic skin disease in childhood, affecting an estimated 7–12% of school-aged children. Although most cases are mild and usually clear up, some patients experience severe or widespread disease that can be physically, socially, and/or emotionally debilitating. Although the underlying cause of Atopic dermatitis remains unclear, its pathogenesis is thought to involve a Th2 cell–mediated allergic inflammatory cascade.

Comparative Biosciences, Inc.’s combined dermatology and immunology expertise make us ideally suited to aid our clients Atopic Dermatitis drug discovery programs.


Atopic Dermatitis Models Overview


• Atopic Dermatitis (AD) is an inflammatory skin disease that frequently occurs in subjects with personal or family history of atopic disease.
• Mechanical injury to the skin by scratching is an important feature of AD and has been shown to induce local expression of IL-10 in patients.
• Epicutaneous sensitization with ovalbumin induction with tape stripping in mice is a useful model.
• This model displays many of the features of human AD, including scaly, inflamed skin, elevated total and specific IgE, histologic infiltration of CD3+ T cells and eosinophils in the dermis, and increased local expression of mRNA for Th2 cytokines.

Basic Study Design


• Five groups of 10 mice per group; vehicle, test article at 3 dose levels, positive control• Housing (46 days on study plus acclimation) in dry environment

• Weekly body weights and daily clinical observations

• Induce atopic dermatitis by albumin and tape stripping at 3 intervals to back skin

• Albumin is applied to tape-stripped skin for 1 week under a Tegaderm dressing followed by a 2 week rest period. Cycle is repeated 3 times

• Daily Draize scoring for up to 1 week during treatment phase to assess macroscopic changes

• Treatment as per sponsor request – systemic or topical

• Necropsy and collect skin

• In-vitro assays as per sponsor request

• Histopathology of skin – special stains and assays as per sponsor request

• Complete report





• CBI provides a consistent, reproducible, validated tape stripping ovalbumin sensitization model in mice as a model for atopic dermatitis

• Characterized by variable dermal thickening, scaliness and reddening macroscopically

• Dermal chronic inflammation with epidermal thickening, dermal fibrosis, increased eosinophils, mast cells and mononuclear cells, and

edema histopathologically

• Dexamethasone provides amelioration of signs and histologic lesions.



Contact Comparative Biosciences, Inc. to discuss a scientific study program for all Studies and Services.

Comparative Biosciences, Inc. · Phone: 408.738.9260